MarketInOut Stock Screener Log In | Sign Up

Aligos Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/18/2026 16:00
Aligos Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization10.93 mln
Float4.85 mln
Earnings Date03/11/2027

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

6.72
Highly suspicious

1-Year Forecast

36.88
Transformational upside

Relative Strength

0 / 100
Severely lagging

Debt / Equity

0.11
Very low leverage

Pre-Tax Margin

-231%
Severely loss-making

Business Description

Aligos Therapeutics is a clinical-stage company working to develop new medicines for patients with serious liver and viral diseases that currently have limited treatment options. Founded in 2018 and based in South San Francisco, the company has several drug candidates advancing through clinical trials, targeting conditions such as fatty liver disease, obesity, hepatitis B, and coronavirus infections. Aligos works alongside research partners including Emory University and KU Leuven to support its drug discovery and development efforts.

Key Fundamentals

EPS-6.46
ROE-131
RPS3.23
ROIC-514
ROA-81.69
EBITDA, mln-71.67
EV / EBITDA-0.32
EV / EBIT-0.31
Revenue, mln31.52
EV / Revenue0.72

Quote Details

Last 1.30
Change -0.06 (-4.41%)
Open 1.39
Volume 108,812
Turnover 141,456
Average Volume 70,167

Financial Ratios

Pre-Tax Profit Margin-231
Leverage Ratio4.17
Current Ratio2.19
Price / Book0.80
Price / Tangible Book0.80
Debt / Equity0.11
Price / Sales1.35

Financial Strength

Altman Z-Score-16.16
Piotroski F-Score 4 / 9
Beneish M-Score6.72
1-Year Target Price36.88
Short Ratio20.50
Short % of Float12.75

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -39.81% 2 / 100   
1 Month -74.16% 1 / 100   
2 Months -80.8% 3 / 100   
6 Months -76.79% 7 / 100   
1 Year -81.48% 9 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog